Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...

The first clinical guidelines on the use of blood biomarker tests could help clinicians choose the most appropriate test to ...

A computer program predicts with more than 75% accuracy who will develop dementia in the near future.

A new study shows that the way amyloid proteins—implicated in Alzheimer's disease—assemble into fibrils can be significantly ...

New research involving nearly 93,000 adults reveals that following a Mediterranean-style eating pattern significantly reduces ...

Data from Most Deeply Characterized Cohort Across Alzheimer's Disease Released by Global Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Among 24 such systems (called devices in FDA parlance) authorized since 2015, FDA summaries for 14 lacked data on the ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.